Pharmacokinetic parameters and killing rates in serum of volunteers receiving amoxicillin, cefadroxil or cefixime alone or associated with niflumic acid or paracetamol. 1998

H Carsenti-Etesse, and R Farinotti, and J Durant, and P M Roger, and F De Salvador, and E Bernard, and B Rouveix, and P Dellamonica
University Hospital, Archet, Nice, France.

Pharmacokinetic parameters and killing rates in serum of volunteers receiving amoxicillin, cefadroxil or cefixime alone or associated with niflumic acid or paracetamol were studied. Niflumic acid (250 mg) or analgesic and antipyretic drugs such as paracetamol (500 mg) are often combined with antibiotics to avoid inflammation and pain in acute ear, nose and throat diseases. Pharmacokinetic interactions between these two classes of drugs have been described in experimental models, and exceptionally in humans. The aim of the present investigation was to study the interactions of these two drugs with three antibiotics (amoxicillin 500 mg x 2, cefadroxil 500 mg x 2, cefixime 200 mg and one placebo capsule) on pharmacodynamic parameters and on rate of killing in the serum of six healthy volunteers receiving the antibiotic associated or not with the product in a randomized cross-over double-blind trial. The bacteria most often involved in sinusitis, bronchitis and otitis media (Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus) three target diseases for oral cephalosporins and amoxicillin, were chosen for bacteriological study. Blood samples were obtained at 0.25, 0.50, 1, 1.5, 2, 4, 6 and 12 h after oral administration of antibiotics alone or associated with the drugs. There was a wash-out period of at least 1 week between the eleven sequences. Antibiotics were measured by two methods: bioassay and high performance liquid chromatography (HPLC). All serum samples obtained at peak level, 4 and 6 h were tested for killing rate. Area under the time kill curve was calculated by the trapezoidal rule method and relative bioactivity in percent was defined as follows: (AUC control - AUC test)/AUC control x 100. No pharmacokinetic interaction was found in the AUC and T1/2 of the plasma concentrations of the antibiotics or associated with the drugs, regardless of dose, as determined by HPLC or microbiological assay. For these beta-lactam antibiotics killing rate was found to be time-dependent. Bactericidal activity was improved on H. influenzae when cefixime was associated with niflumic acid and became concentration-dependent. A significant concentration relation was also found with niflumic acid or paracetamol associated with cefixime on Strep. pneumoniae.

UI MeSH Term Description Entries
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009544 Niflumic Acid An analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis. Donalgin,Flunir,Niflactol,Niflugel,Nifluril,Acid, Niflumic
D002434 Cefadroxil Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative. 4-Hydroxycephalexin,5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))-,BL-S 578,BL-S578,Bidocef,Cefadroxil Anhydrous,Cefadroxil Monohydrate,Cephadroxyl,Duricef,S-578,S578,Ultracef,4 Hydroxycephalexin,BL S 578,BL S578,BLS 578,BLS578,S 578
D002439 Cefotaxime Semisynthetic broad-spectrum cephalosporin. Benaxima,Biosint,Cefotaxim,Cefotaxime Sodium,Cefradil,Cephotaxim,Claforan,Fotexina,HR-756,Kendrick,Klaforan,Primafen,Ru-24756,Taporin,HR 756,HR756,Ru 24756,Ru24756,Sodium, Cefotaxime
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005260 Female Females
D006193 Haemophilus influenzae A species of HAEMOPHILUS found on the mucous membranes of humans and a variety of animals. The species is further divided into biotypes I through VIII. Bacterium influenzae,Coccobacillus pfeifferi,Haemophilus meningitidis,Hemophilus influenzae,Influenza-bacillus,Mycobacterium influenzae

Related Publications

H Carsenti-Etesse, and R Farinotti, and J Durant, and P M Roger, and F De Salvador, and E Bernard, and B Rouveix, and P Dellamonica
December 1991, Pathologie-biologie,
H Carsenti-Etesse, and R Farinotti, and J Durant, and P M Roger, and F De Salvador, and E Bernard, and B Rouveix, and P Dellamonica
December 1986, Antimicrobial agents and chemotherapy,
H Carsenti-Etesse, and R Farinotti, and J Durant, and P M Roger, and F De Salvador, and E Bernard, and B Rouveix, and P Dellamonica
February 1986, Antimicrobial agents and chemotherapy,
H Carsenti-Etesse, and R Farinotti, and J Durant, and P M Roger, and F De Salvador, and E Bernard, and B Rouveix, and P Dellamonica
July 1987, Antimicrobial agents and chemotherapy,
H Carsenti-Etesse, and R Farinotti, and J Durant, and P M Roger, and F De Salvador, and E Bernard, and B Rouveix, and P Dellamonica
January 1988, The Journal of antimicrobial chemotherapy,
H Carsenti-Etesse, and R Farinotti, and J Durant, and P M Roger, and F De Salvador, and E Bernard, and B Rouveix, and P Dellamonica
January 1981, Revista medica de Chile,
H Carsenti-Etesse, and R Farinotti, and J Durant, and P M Roger, and F De Salvador, and E Bernard, and B Rouveix, and P Dellamonica
March 1992, Antimicrobial agents and chemotherapy,
H Carsenti-Etesse, and R Farinotti, and J Durant, and P M Roger, and F De Salvador, and E Bernard, and B Rouveix, and P Dellamonica
May 1987, The Journal of antimicrobial chemotherapy,
H Carsenti-Etesse, and R Farinotti, and J Durant, and P M Roger, and F De Salvador, and E Bernard, and B Rouveix, and P Dellamonica
September 1991, Pathologie-biologie,
H Carsenti-Etesse, and R Farinotti, and J Durant, and P M Roger, and F De Salvador, and E Bernard, and B Rouveix, and P Dellamonica
January 2010, Acta poloniae pharmaceutica,
Copied contents to your clipboard!